Breast cancer is a common cancer affecting a large number of patients. Notably, 5–10% of
all breast cancer patients are genetically predisposed to cancers. Although the most …

Ovarian cancer is not a single disease and can be subdivided into at least five different
histological subtypes that have different identifiable risk factors, cells of origin, molecular …

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants …

PURPOSE To provide recommendations on the use of poly (ADP-ribose) polymerase
inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer …

PURPOSE To provide recommendations on genetic and tumor testing for women diagnosed
with epithelial ovarian cancer based on available evidence and expert consensus …

Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients …

Epithelial ovarian cancer (EOC) is one of the cancers most influenced by hereditary factors.
A fourth to a fifth of unselected EOC patients carry pathogenic variants (PVs) in a number of …

Importance Germline mutations inBRCA1andBRCA2are relatively common in women with
ovarian, fallopian tube, and peritoneal carcinoma (OC) causing a greatly increased lifetime …

Abstract On December 19, 2014, the FDA approved olaparib capsules (Lynparza;
AstraZeneca) for the treatment of patients with deleterious or suspected deleterious germline …

The fallopian tube secretory cell is the cell of origin for the majority of ovarian cancers.
Although it remains unclear what triggers neoplastic transformation of these cells, certain …